Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones (GlobeNewswire) - Mar 25, 2024 - "STRO-002:...Enrollment of REFRαME-P1, a registration-enabling trial for pediatric patients with CBF/GLIS AML, is expected to be initiated in the second half of 2024....Additional Pipeline Development and Collaboration Updates: (i) Sutro plans to submit an IND for STRO-003, a ROR1-targeting ADC, in 2024; (ii) Sutro plans to submit an IND for STRO-004, a tissue factor-targeting ADC, in 2025."
IND • New trial • Acute Myelogenous Leukemia • Solid Tumor
|